Product Name: CD33 Antibody [C33/69]
Species Reactivity: Human
Tested Applications: Flow, Func
Applications: Functional Testing: order BSA/azide-free formatFlow Cytometry: 0.5-1 ug/million cellsIF: 0.5-1 ug/mlThe concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Recombinant human CD33 protein was used as the immunogen for this antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 591778-70-0
Product: CP-640186 (hydrochloride)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: CD33 Antibody: p67, SIGLEC3, SIGLEC-3, Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3
Accession NO.:
Protein Ino:
Official Symbol: CD33
Geneid: 945
Background: This antibody recognizes a 67kDa glycoprotein, which is identified as CD33 (HLDA IV; WS Code M-505). CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia. CD33 is expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells. It is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.
PubMed ID:http://aac.asm.org/content/34/7/1354.abstract
